Skip to main content

Table 1 Baseline characteristics of all patients with cirrhosis included in the study (n = 234) and those with an available ECG from pre-transplant evaluation (n = 186)

From: Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis

  All patients (n = 234) Patients with an available ECG (n = 186)
Age 52 (10.5) 52 (11)
Male sex 162 (69%) 133 (72%)
Etiology of liver cirrhosis   
 Alcoholic liver disease or mixed 85 (36%) 71 (38%)
 Viral liver disease 55 (23.5%)1 47 (25.5%)2
 Cholestatic liver disease 42 (18%)3 33 (18%)4
 Autoimmune hepatitis 14 (6%) 12 (6.5%)
 Cryptogenic/NASH cirrhosis 20 (8.5%) 18 (9.5%)
 Other 18 (8%)5 5 (2.5%)
Severity of liver cirrhosis   
 Child Pugh Score 9 (2.2) 8.9 (2.2)
 MELD 16.5 (6.8) 16.2 (6.5)
Complications of liver cirrhosis   
 History of variceal bleeding 59 (25%) 45 (24%)
 Ascites at evaluation 167 (71%) 132 (71%)
 Hepatocellular carcinoma in explant 26 (11%) 23 (12.5%)
 Hepatorenal syndrome 43 (18%) 33 (17.5%)
Mean arterial pressure (mmHg) 85.5 (12) 85 (11.5)
Heart rate 72 (11) 72 (12)
Glomerular filtration rate (ml/h/1.73sqm) 83 (29.5) 83 (29.5)
CAD 18 (8%) 13 (7%)
Diabetes mellitus 28 (12%) 37 (20%)
History of arterial hypertension 48 (20%) 23 (12%)
Current or ex-smoker 118 (43%) 92 (49%)
β-Blockers at pre-transplant evaluation 112 (48%) 92 (49%)
Use of diuretics at evaluation 152 (65%) 123 (66%)
Coronary investigation 6 95 (34.5%) 74 (40%)
  1. Data expressed as mean (SD) or n (%) as appropriate. No statistical difference was seen between the groups with regard to the factors listed in this table. (p > 0.1 for all).
  2. NASH, non-alcoholic steatohepatitis; MELD, model for end-stage liver disease; CAD, Coronary artery disease.
  3. 1Hepatitis C – 30, Hepatitis B - 21, Hepatitis B and C - 4.
  4. 2Hepatitis C - 38, hepatitis B - 28, hepatitis C and hepatitis B – 5.
  5. 3Primary sclerosing cholangitis - 20, Primary biliary cirrhosis – 13.
  6. 4Primary sclerosing cholangitis - 26, Primary biliary cirrhosis - 17.
  7. 5Overlap syndrome - 7, Alpha 1 antitrypsine deficiency – 3, Cholestatic disease and alcoholic liver disease – 2, Secondary sclerosing cholangitis - 2, Wilsons disease - 1, Drug induced liver injury - 1, Cystic fibrosis - 1, and Echinococcal infection/treatment of echinococcal infection - 1.
  8. 6Patients who underwent further investigation for CAD at pre-transplant evaluation such as coronary angiography, myocardial scintigraphy, stress echocardiography and/or treadmill exercise test.